0002056611

IPO filing research

Latigo Biotherapeutics, Inc.

Pharmaceutical Preparations

ipo amended Nasdaq Global Select Market S-1

Latigo Biotherapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-17. Current deal snapshot: exchange Nasdaq Global Select Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Exchange Nasdaq Global Select Market · Ticker LTGO · Underwriters Goldman Sachs & Co. LLC, Jefferies, Leerink Partners

Latigo Biotherapeutics, Inc. is conducting an IPO with an assumed initial public offering price of $ per share, reflecting significant financial challenges and capital needs. The offering includes conversions of convertible preferred stock and notes, a reverse stock split, and shares reserved under the 2026 Employee Stock Purchase Plan (ESPP). The company reported net losses of $61.2M (2024) and $109.2M (2025), with an accumulated deficit of $266.1M as of March 2026, highlighting its reliance on future funding to advance clinical-stage therapies.

2026-07-17 · 0001193125-26-307306

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-06-05 · 0001193125-26-259845

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-05-18 · 0001193125-26-227442

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-03-27 · 0001193125-26-129261

Comparable Deals

17 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 17 using nearest neighbors.

Showing top 8 by similarity.

-8.2%

Median day-1

47%

Above issue

-2.1%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Standard Nuclear, Inc. STDN

2026-07-16 $150M Day 1: -8.2% Wk 1: -24.9%

same SIC grouprecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Recent News

No recent news stored for this issuer.